The aim of the study was to compare high-versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin as primary chemotherapy for suboptimal stage III and IV ovarian cancer.One hundred forty-five patients were randomized to receive six courses of cisplatin 50 or 100 mg/m2 plus epidoxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2. The two treatment arms were well balanced; all patients had greater than 2 cm and 37.2\% had greater than 5 cm of residual disease; 29.6\% had stage IV disease.Patients in the high-dose arm received a double dose-intensity and double total dose of cisplatin. The high-dose regimen induced significantly more episodes of leukopenia (47.8\% v 32.8\%, P = .05), thrombocytopenia (21.7\% v 3.2\%, P = .003), anemia (37.6\% v 12.5\%, P = .002), nephrotoxicity (six v one patient), and neurotoxicity (30.4\% v 6.3\%, P = .002). There were no significant differences in efficacy in terms of clinical response rate (high-dose 57.5\% v low-dose 61.1\%), pathologic complete response (CR) (9.6\% v 18.1\%), median survival times (29 v 24 months), and median progression-free survival (18 v 13 months).This study shows that doubling the dose-intensity and total dose of cisplatin in combination with epidoxorubicin and cyclophosphamide has significant toxic effects and does not improve clinical outcome in patients with suboptimal ovarian cancer.

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest / Conte, Pierfranco; M., Bruzzone; F., Carnino; A., Gadducci; R., Algeri; A., Bellini; F., Boccardo; I., Brunetti; E., Catsafados; S., Chiara; G., Foglia; L., Gallo; L., Iskra; S., Mammoliti; G., Parodi; N., Ragni; R., Rosso; S., Rugiati; A., Rubagotti. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 14:(1996), pp. 351-356.

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.

CONTE, Pierfranco;
1996-01-01

Abstract

The aim of the study was to compare high-versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin as primary chemotherapy for suboptimal stage III and IV ovarian cancer.One hundred forty-five patients were randomized to receive six courses of cisplatin 50 or 100 mg/m2 plus epidoxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2. The two treatment arms were well balanced; all patients had greater than 2 cm and 37.2\% had greater than 5 cm of residual disease; 29.6\% had stage IV disease.Patients in the high-dose arm received a double dose-intensity and double total dose of cisplatin. The high-dose regimen induced significantly more episodes of leukopenia (47.8\% v 32.8\%, P = .05), thrombocytopenia (21.7\% v 3.2\%, P = .003), anemia (37.6\% v 12.5\%, P = .002), nephrotoxicity (six v one patient), and neurotoxicity (30.4\% v 6.3\%, P = .002). There were no significant differences in efficacy in terms of clinical response rate (high-dose 57.5\% v low-dose 61.1\%), pathologic complete response (CR) (9.6\% v 18.1\%), median survival times (29 v 24 months), and median progression-free survival (18 v 13 months).This study shows that doubling the dose-intensity and total dose of cisplatin in combination with epidoxorubicin and cyclophosphamide has significant toxic effects and does not improve clinical outcome in patients with suboptimal ovarian cancer.
14
351
356
High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest / Conte, Pierfranco; M., Bruzzone; F., Carnino; A., Gadducci; R., Algeri; A., Bellini; F., Boccardo; I., Brunetti; E., Catsafados; S., Chiara; G., Foglia; L., Gallo; L., Iskra; S., Mammoliti; G., Parodi; N., Ragni; R., Rosso; S., Rugiati; A., Rubagotti. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 14:(1996), pp. 351-356.
Conte, Pierfranco; M., Bruzzone; F., Carnino; A., Gadducci; R., Algeri; A., Bellini; F., Boccardo; I., Brunetti; E., Catsafados; S., Chiara; G., Foglia; L., Gallo; L., Iskra; S., Mammoliti; G., Parodi; N., Ragni; R., Rosso; S., Rugiati; A., Rubagotti
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/739343
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 95
  • ???jsp.display-item.citation.isi??? 88
social impact